Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.

Heck, Matthias M; Retz, Margitta; Bandur, Miriam; Souchay, Marc; Vitzthum, Elisabeth; Weirich, Gregor; Schuster, Tibor; Autenrieth, Michael; Kübler, Hubert; Maurer, Tobias; Thalgott, Mark; Herkommer, Kathleen; Gschwend, Jürgen E; Nawroth, Roman

doi:10.1158/1078-0432.CCR-17-3771

2018

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Dokumenttyp:: Journal Article
Autor(en):: Heck, Matthias M; Retz, Margitta; Bandur, Miriam; Souchay, Marc; Vitzthum, Elisabeth; Weirich, Gregor; Schuster, Tibor; Autenrieth, Michael; Kübler, Hubert; Maurer, Tobias; Thalgott, Mark; Herkommer, Kathleen; Gschwend, Jürgen E; Nawroth, Roman
Abstract:: Molecular lymph node (LN) analysis using quantitative polymerase chain reaction (qPCR) detects LN metastases with higher sensitivity than histopathology. However, the prognostic role of molecular LN status in prostate cancer patients treated with radical prostatectomy (RP) and extended pelvic LN dissection (ePLND) is unclear. To investigate the association of molecular compared with histopathologic LN status with biochemical recurrence. Patients with intermediate and high-risk prostate cancer were prospectively enrolled and underwent RP with ePLND, including the obturator, internal, external, and the common iliac region. LNs >=3 mm were bisected and examined by standard histopathology and qPCR for Kallikrein3 (KLK3) expression. Biochemical recurrence was defined by confirmed postoperative PSA > 0.2 ng/mL. In 111 patients, 2,411 of 3,173 removed LNs were examined by both methods. Histopathology detected 68 LN metastases in 28 (25%) patients. Molecular analysis confirmed elevated KLK3 expression in 65 histopathologic LN metastases of all 28 pN1 patients (pN1/molN1) and additionally reclassified 224 histopathologic negative LNs and 32 (29%) pN0 patients as LN-positive (pN0/molN1).At a median follow-up of 48 months, 52 (47%) patients developed biochemical recurrence. Median biochemical recurrence-free survival was 9 months [95% confidence interval (CI), 0.0-20.1] in pN1/molN1 patients, 24 months (95% CI, 1.7-46.3) in pN0/molN1 patients and was not reached in pN0/molN0 patients ( < 0.001). On multivariable Cox regression analysis, molecular LN status [HR 4.1 (95% CI, 1.9-8.8), < 0.001] but not histopathologic LN status [HR 1.5 (95% CI, 0.8-3.0), = 0.198] was confirmed as independent predictor of biochemical recurrence. Molecular LN analysis identified pN0 patients with a high risk of biochemical recurrence and provided superior prognostic information in comparison with histopathology alone. .
Zeitschriftentitel:: Clin Cancer Res
Jahr:: 2018
Band / Volume:: 24
Heft / Issue:: 10
Seitenangaben Beitrag:: 2342-2349
Sprache:: eng
Volltext / DOI:: doi:10.1158/1078-0432.CCR-17-3771
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/29463560
Print-ISSN:: 1078-0432
TUM Einrichtung:: Institut für Allgemeine Pathologie und Pathologische Anatomie; Urologische Klinik und Poliklinik
BibTeX